Biology of Germ Cell Tumors

Hematology/Oncology Clinics of North America

Volumn 25, Issue 3, 2011, Pages 457-471

  Ma, Yuk Ting ^a   Cullen, Michael H ^a   Hussain, Syed A ^a,b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Biology; Cisplatin resistance; Germ cell tumors; Testicular

Indexed keywords

5 METHYLCYTOSINE; CISPLATIN; CYCLIN D2; DNA; DNA METHYLTRANSFERASE 3B; ETHANOLAMINE KINASE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; TRANSCRIPTION FACTOR NANOG;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL MEMBRANE; CHORIOCARCINOMA; CHROMOSOME 7; DNA SYNTHESIS; DRUG METABOLISM; DRUG RESISTANCE; EMBRYO DEVELOPMENT; EMBRYONAL CARCINOMA; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GERM CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; NON SEMINOMATOUS GERMINOMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MOLECULAR BIOLOGY; NEOPLASMS, GERM CELL AND EMBRYONAL; TESTICULAR NEOPLASMS;

EID: 79955791091     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2011.03.004     Document Type: Review

References (114)

1. Looijenga L.H., Oosterhuis J.W. Pathogenesis of testicular germ cell tumours. Rev Reprod 1999, 4:90-100.
2. Skakkebaek N.E. Possible carcinoma-in-situ of the testis. Lancet 1972, 2:516-517.
3. Jacobsen G.K., Henriksen O.B., von der Maase H. Carcinoma in situ of testicular tissue adjacent to malignant germ cell tumors: a study of 105 cases. Cancer 1981, 47:2660-2662.
4. Skakkebaek N.E. Carcinoma in situ of the testis: frequency and relationship to invasive germ cell tumours in infertile men. Histopathology 1978, 2:157-170.
5. Von der Maase H., Rørth M., Walbom-Jørgensen S., et al. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J 1986, 293:1398-1401.
6. Skakkebaek N.E., Berthelsen J.G., Giwercman A., et al. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursor of all types of germ cell tumours except spermatocytoma. Int J Androl 1987, 10:19-28.
7. Nielsen H., Nielsen M., Skakkebaek N.E. The fine structure of possible carcinoma-in-situ in the seminiferous tubules in the testes of four infertile men. Acta Pathol Microbiol Scand A 1974, 82:235-248.
8. Rajpert-De Meyts E., Bartkova J., Samson M., et al. The emerging phenotype of the testicular carcinoma in situ germ cell. APMIS 2003, 111:267-278.
9. Koide O., Iwai S., Baba K., et al. Identification of testicular atypical germ cells by an immunohistochemical technique for placental alkaline phosphatase. Cancer 1987, 60:1325-1330.
10. Giwercman A., Cantell L., Marks A. Placental-like alkaline phosphatase as a marker of carcinoma in situ of the testis. Comparison with monoclonal antibodies M2A and 43-9F. APMIS 1991, 99:586-594.
11. Jorgensen N., Rajpert-De Meyts E., Graem N., et al. Expression of immunohistochemical markers for testicular carcinoma in situ by normal human fetal germ cells. Lab Invest 1995, 72:223-231.
12. Rajpert-De Meyts E., Hanstein R., Jorgensen N., et al. Developmental expression of POU5F1 (OCT3/4) in normal and dysgenetic human gonads. Hum Reprod 2004, 19:1338-1344.
13. van Gurp R.J., Oosterhuis J.W., Kalscheuer V., et al. Biallelic expression of the H19 and IGF2 genes in human testicular germ cell tumors. J Natl Cancer Inst 1994, 86:1070-1075.
14. Almstrup K., Hoei-Hansen C.E., Wirkner U., et al. Embryonic stem cell-like features of testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer Res 2004, 64:4736-4743.
15. Skotheim R.I., Lind G.E., Monni O., et al. Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res 2005, 65:5588-5598.
16. Rajpert-De Meyts E., Jørgensen N., Brøndum-Nielsen K., et al. Developmental arrest of germ cells in the pathogenesis of germ cell neoplasia. APMIS 1998, 106:198-204.
17. Rajpert-De Meyts E., Skakkebaek N.E. The possible role of sex hormones in the development of testicular cancer. Eur Urol 1993, 23:54-59.
18. Chaganti R.S., Houldsworth J. Genetics and biology of adult human male germ cell tumors. Cancer Res 2000, 60:1475-1482.
19. Dieckmann K.P., Skakkebaek N.E. Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 1999, 83:815-822.
20. Atkin N.B., Baker M.C. Specific chromosome change, i(12p), in testicular tumours?. Lancet 1982, 11:1349.
21. Suijkerbuijk R.F., Sinke R.J., Meloni A.M., et al. Overrepresentation of chromosome 12p sequences and karyotypic evolution in i(12p)-negative testicular germ-cell tumors revealed by fluorescence in situ hybridization. Cancer Genet Cytogenet 1993, 70:85-93.
22. Rodriguez E., Houldsworth J., Reuter V.E., et al. Molecular cytogenetic analysis of i(12p)-negative human male germ cell tumors. Genes Chromosomes Cancer 1993, 8:230-236.
23. Mostert M.M., van de Pol M., Olde Weghuis D., et al. Comparative genomic hybridization of germ cell tumors of the adult testis: confirmation of karyotypic findings and identification of a 12p amplicon. Cancer Genet Cytogenet 1996, 89:146-152.
24. Korn M.W., Olde Weghuis D.E., Suijkerbuijk R.F., et al. Detection of chromosomal DNA gains and losses in testicular germ cell tumors by comparative genomic hybridization. Genes Chromosomes Cancer 1996, 17:78-87.
25. Suijkerbuijk R.F., Sinke R.J., Olde Weghuis D.E., et al. Amplification of chromosome subregion 12p11.2-12.1 in a metastasis of an i(12p)-negative seminoma: relationship to tumor progression?. Cancer Genet Cytogenet 1994, 78:145-152.
26. Mostert M.C., Verkerk A.J., van de Pol M., et al. Identification of the critical region of 12p over-representation in testicular germ cell tumors of adolescents and adults. Oncogene 1998, 16:2617-2627.
27. Roelofs H., Mostert M.C., Pompe K., et al. Restricted 12p amplification and RAS mutation in human germ cell tumors of the adult testis. Am J Pathol 2000, 57:1155-1166.
28. Kraggerud S.M., Skotheim R.I., Szymanska J., et al. Genome profiles of familial/bilateral and sporadic testicular germ cell tumors. Genes Chromosomes Cancer 2002, 34:168-174.
29. Henegariu O., Heerema N.A., Thurston V., et al. Characterization of gains, losses, and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization. Cancer Genet Cytogenet 2004, 148:14-20.
30. Houldsorth J., Reuter V., Bosl G.J., et al. Aberrant expression of cyclin D2 is an early event in human male germ cell tumorigenesis. Cell Growth Differ 1997, 8:293-299.
31. Zafarana G., Gillis A.J., van Gurp R.J., et al. Coamplification of DAD-R, SOX5 and EKI1 in human testicular seminomas, with specific overexpression of DAD-R, correlates with reduced levels of apoptosis and earlier clinical manifestation. Cancer Res 2002, 62:1822-1831.
32. Rodriguez S., Jafer O., Goker H., et al. Expression profile of genes from 12p in testicular germ cell tumors of adolescents and adults associated with i(12p) and amplification at 12p1.2-p12.1. Oncogene 2003, 22:1880-1891.
33. Bourdon V., Naef F., Rao P.H., et al. Genomic and expression analysis of the 12p11-p12 amplicon using EST arrays identifies two novel amplified and overexpressed genes. Cancer Res 2002, 62:6218-6223.
34. Ezeh U.I., Turek P.J., Reijo R.A., et al. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005, 104:2255-2265.
35. Korkola J.E., Houldsworth J., Chadalavada R.S., et al. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006, 66:820-827.
36. Ottesen A.M., Skakkebaek N.E., Lundsteen C., et al. High-resolution comparative genomic hybridization detects extra chromosome arm 12p material in most cases of carcinoma in situ adjacent to overt germ cell tumors, but not before the invasive tumor development. Genes Chromosomes Cancer 2003, 38:117-125.
37. Geurts van Kessel A., van Drunen E., de Jong B., et al. Chromosome 12q heterozygosity is retained in i(12p)-positive testicular germ cell tumor cells. Cancer Genet Cytogenet 1989, 40:129-134.
38. Summersgill B., Osin P., Lu Y.J., et al. Chromosomal imbalances associated with carcinoma in situ and associated testicular germ cell tumours of adolescents and adults. Br J Cancer 2001, 85:213-219.
39. Skotheim R.I., Monni O., Mousses S., et al. New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res 2002, 62:2359-2364.
40. McIntyre A., Summersgill B., Jafar O., et al. Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones. Oncogene 2004, 23:9142-9147.
41. Skotheim R.I., Autio R., Lind G.E., et al. Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression change. Cell Oncol 2006, 28:315-326.
42. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428.
43. Smiraglia D.J., Szymanska J., Kraggerud S.M., et al. Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene 2002, 21:3909-3916.
44. Koul S., Houldsworth J., Mansukhani M.M., et al. Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer 2002, 1:8.
45. Smith-Sørensen B., Lind G.E., Skotheim R.I., et al. Frequent promoter hypermethylation of the O6-Methylguanine-DNA Methyltransferase (MGMT) gene in testicular cancer. Oncogene 2002, 21:8878-8884.
46. Honorio S., Agathanggelou A., Wernet N., et al. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma germ cell tumours. Oncogene 2003, 22:461-466.
47. Almstrup K., Hoei-Hansen C.E., Nielsen J.E., et al. Genome-wide gene expression profiling of testicular carcinoma in situ progression into overt tumours. Br J Cancer 2005, 92:1934-1941.
48. Netto G.J., Nakai Y., Nakayama M., et al. Global DNA hypomethylation in intratubular germ cell neoplasia and seminoma, but not in nonseminomatous male germ cell tumors. Mod Pathol 2008, 21:1337-1344.
49. Wermann H., Stoop H., Gillis A.J., et al. Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J Pathol 2010, 221:433-443.
50. De Jong J., Weeda S., Gillis A.J.M., et al. Differential methylation of the OCT3/4 upstream region in primary human testicular germ cell tumors. Oncol Rep 2007, 18:127-132.
51. Port M., Schmelz H.U., Stockinger M., et al. Gene expression profiling in seminoma and nonseminoma. J Clin Oncol 2005, 23:58-69.
52. Okada K., Katagiri T., Tsunoda T., et al. Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int J Oncol 2003, 23:1615-1635.
53. Korkola J.E., Houldsworth J., Dobrzynski D., et al. Gene expression-based classification of nonseminomatous male germ cell tumors. Oncogene 2005, 24:5101-5107.
54. Juric D., Sale S., Hromas R.A., et al. Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures. Proc Natl Acad Sci U S A 2005, 102:17763-17768.
55. Hofer M.D., Browne T.J., He L., et al. Identification of two molecular groups of seminomas by using expression and tissue microarrays. Clin Cancer Res 2005, 11:5722-5729.
56. Sugimura J., Foster R.S., Cummings O.W., et al. Gene expression profiling of early- and late-relapse nonseminomatous germ cell tumor and primitive neuroectodermal tumor of the testis. Clin Cancer Res 2004, 10:2368-2378.
57. Korkola J.E., Houldsworth J., Feldman D.R., et al. Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors. J Clin Oncol 2009, 27:5240-5247.
58. Aladjem M.I., Spike B.T., Rodewald L.W., et al. ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage. Curr Biol 1998, 8:145-155.
59. 1 arrest and protection from apoptosis in embryonic stem cells after ionizing radiation. Proc Natl Acad Sci U S A 2004, 101:14443-14448.
60. Oosterhuis J.W., Andrews P.W., Knowles B.B., et al. Effects of cis-platinum on embryonal cancer cell lines in vitro. Int J Cancer 1984, 34:133-139.
61. Walker M.C., Parris C.N., Masters J.R. Differential sensitivities to chemotherapeutic drugs between testicular and bladder cancer cells. J Natl Cancer Inst 1987, 79:213-216.
62. Fry A.M., Chresta C.M., Davies S.M., et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991, 51:6592-6595.
63. Masters J.R., Osborne E.J., Walker M.C., et al. Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs. Int J Cancer 1993, 53:340-346.
64. Parris C.N., Arlett C.F., Lehmann A.R., et al. Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines. Int J Radiat Biol Relat Stud Phys Chem Med 1988, 53:599-608.
65. Masters J.R., Köberle B. Curing metastatic cancer: lessons from testicular germ-cell tumours. Nat Rev Cancer 2003, 3:517-525.
66. Peng H.Q., Hogg D., Malkin D., et al. Mutations of the p53 gene do not occur in testis cancer. Cancer Res 1993, 53:3574-3578.
67. Heimdal K., Lothe R.A., Lystad S., et al. No germline TP53 mutations detected in familial and bilateral testicular cancer. Genes Chromosomes Cancer 1993, 6:92-97.
68. Kersemaekers A.M., Mayer F., Molier M., et al. Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 2002, 20:1551-1561.
69. Chresta C.M., Masters J.R., Hickman J.A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996, 56:1834-1841.
70. L and sensitises human testicular germ cell tumours to chemotherapy-induced apoptosis. Oncogene 1998, 18:1457-1464.
71. Burger H., Nooter K., Boersma A.W., et al. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines. Br J Cancer 1998, 77:1562-1567.
72. Mayer F., Stoop H., Scheffer G.L., et al. Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 2003, 9:767-773.
73. Nuti F., Luciani P., Marinari E., et al. Seladin-1 and testicular germ cell tumours: new insights into cisplatin responsiveness. J Pathol 2009, 219:491-500.
74. Fichtinger-Schepman A.M., van der Veer J.L., den Hartog J.H., et al. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 1985, 24:707-713.
75. Zamble D.B., Mu D., Reardon J.T., et al. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996, 35:10004-10013.
76. Bedford P., Fichtinger-Schepman A.M., Shellard S.A., et al. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 1988, 48:3019-3024.
77. Köberle B., Masters J.R., Hartley J.A., et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999, 9:273-276.
78. Welsh C., Day R., McGurk C., et al. Reduced levels of XPA, ERRC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004, 110:352-361.
79. Usanova S., Piee-Staffa A., Sied U., et al. Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 2010, 9:248.
80. Ohndorf U.M., Rould M.A., He Q., et al. Basis for the recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 1999, 399:708-712.
81. Billings P.C., Engelsberg B.N., Hughes E.N. Proteins binding to cisplatin-damaged DNA in human cell lines. Cancer Invest 1994, 12:597-604.
82. Huang J.C., Zamble D.B., Reardon J.T., et al. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A 1994, 91:10394-10398.
83. Zamble D.B., Mikata Y., Eng C.E., et al. Testis-specific HMG-domain protein alters the response of cells to cisplatin. J Inorg Biochem 2002, 91:451-462.
84. Ohndorf U.M., Whitehead J.P., Raju N.L., et al. Binding to tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts. Biochemistry 1997, 36:14807-14815.
85. Trimer E.E., Zamble D.B., Lippard S.J., et al. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities. Biochemistry 1998, 37:352-362.
86. Safaei R., Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005, 53:13-23.
87. Kuo M.T., Chen H.H., Song I.S., et al. The roles of copper transporters in cisplatin resistance. Cancer Metastasis Rev 2007, 26:71-83.
88. Song I.S., Savaraj N., Siddik Z.H., et al. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 2004, 3:1543-1549.
89. Komatsu M., Sumizawa T., Mutoh M., et al. Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 2000, 60:1312-1316.
90. Samimi G., Safaei R., Katano K., et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 2004, 10:4661-4669.
91. Katano K., Safaei R., Samimi G., et al. The copper export pump ATP7B modulates the cellular pharmacology of carboplatin in ovarian carcinoma cells. Mol Pharmacol 2003, 64:466-473.
92. Nakayama K., Kanzaki A., Terada K., et al. Prognostic value of the cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy. Clin Cancer Res 2004, 10:2804-2811.
93. Ohbu M., Ogawa K., Konno S., et al. Copper-transporting P-type adenosine triphosphate (ATP7B) is expressed in human gastric carcinoma. Cancer Lett 2003, 189:33-38.
94. Masters J.R., Thomas R., Hall A.G., et al. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways. Eur J Cancer 1996, 32A:1248-1253.
95. Koropatnick J., Kloth D.M., Kadhim S., et al. Metallothionein expression and resistance to cisplatin in a human germ cell tumor cell line. J Pharmacol Exp Ther 1995, 275:1681-1687.
96. Meijer C., Timmer A., De Vries E.G., et al. Role of metallothionein in cisplatin sensitivity of germ cell tumours. Int J Cancer 2000, 85:777-781.
97. Fink D., Nebel S., Aebi S., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1990, 56:4881-4889.
98. Aebi S., Kurdi-Haidar B., Gordon R., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996, 56:3087-3090.
99. Fink D., Zheng H., Nebel S., et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997, 57:1841-1845.
100. Mayer F., Gillis A.J., Dinjens W., et al. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 2002, 62:2758-2760.
101. Olasz J., Mándoky L., Géczi L., et al. Influence of hMLH1 methylation, mismatch repair deficiency and microsatellite instability on chemoresistance of testicular germ-cell tumours. Anticancer Res 2005, 25:4319-4324.
102. Velasco A., Riquelme E., Schultz M., et al. Microsatellite instability and loss of heterozygosity have distinct prognostic value for testicular germ cell tumor recurrence. Cancer Biol Ther 2004, 3:1152-1158.
103. Velasco A., Corvalan A., Wistuba I.I., et al. Mismatch repair expression in testicular cancer predicts recurrence and survival. Int J Cancer 2008, 122:1774-1777.
104. Honecker F., Wermann H., Mayer F., et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 2009, 27:2129-2136.
105. Houldsworth J., Xiao H., Murty V.V., et al. Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 1998, 16:2345-2349.
106. Burger H., Nooter K., Boersma A.W., et al. Distinct p53-independent apoptotic cell death signalling pathways in testicular germ cell tumour cell lines. Int J Cancer 1999, 81:620-628.
107. Spierings D.C., de Vries E.G., Vellenga E., et al. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumour cell line. Cell Death Differ 2003, 10:808-822.
108. Schweyer S., Soruri A., Meschter O., et al. Cisplatin-induced apoptosis in human malignant testicular germ cell lines depends on MEK/ERK activation. Br J Cancer 2004, 91:589-598.
109. Mueller T., Vogt W., Simon H., et al. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 2003, 63:513-521.
110. Köberle B., Payne J., Grimaldi K.A., et al. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction. Biochem Pharmacol 1996, 52:1729-1734.
111. Rao P.H., Houldsworth J., Palanisamy N., et al. Chromosomal amplification is associated with cisplatin resistance of human germ cell tumors. Cancer Res 1998, 58:4260-4263.
112. Wilson C., Yang J., Streffod J., et al. Overexpression of genes on 16q associated with cisplatin resistance of testicular germ cell tumor cell lines. Genes Chromosomes Cancer 2005, 43:211-216.
113. Noel E.E., Yeste-Velasco M., Mao X., et al. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol 2010, 176:2607-2615.
114. Beyrouthy M.J., Garner K.M., Hever M.P., et al. High DNA methyltransferase 3B expression mediates 5-azadeoxycytidine hypersensitivity in testicular germ cell tumors. Cancer Res 2009, 69:9360-9366.